1302580-98-8

Basic information

• Product Name: 1-(5-fluoro-pyridin-2-yl)-cyclopropanecarboxylic acid
• CAS NO: 1302580-98-8
• Molecular Weight: 181.166
• Mol File: 1302580-98-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(5-fluoro-pyridin-2-yl)-cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-fluoro-pyridin-2-yl)-cyclopropanecarboxylic acid(1302580-98-8)
• EPA Substance Registry System: 1-(5-fluoro-pyridin-2-yl)-cyclopropanecarboxylic acid(1302580-98-8)

Safety Data

• Hazardous Substances Data: 1302580-98-8(Hazardous Substances Data)

Usage

Structure

Cyclopropane carboxylic acid derivative with a fluoropyridine group attached to the cyclopropane ring

Type of compound

Chemical compound

Potential applications

Medicinal chemistry, specifically in the development of pharmaceutical drugs

Significance

Valuable building block for the synthesis of novel bioactive compounds

Research implications

Further study may lead to the discovery of new drug candidates with therapeutic potential

Upstream product

• 1302580-97-7 1-(5-fluoropyridin-2-yl)cyclopropanecarbonitrile 
• 84476-99-3 2,5-difluoropyridine 

Relevant articles and documents

OXAZOLINE DERIVATIVES

The invention relates to compounds of formula I wherein the definitions of X, R and R1 are as defined herein. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.